Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Mirabegron (Primary) ; Solifenacin
- Indications Overactive bladder
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 24 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Jan 2013 New trial record